The development of combinational therapies incorporating AREG inhibitors holds great promise for remodeling the TME and enhancing therapeutic outcomes in various cancer types, including colorectal cancer [213,214], pancreatic cancer [190,215], head and neck cancer [29,216], ovarian cancer [181,187], and lung cancer [18,187,201,202,217,218]. Here, AREG is linked to ovarian cancer.